Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity [0.03%]
瑞穆チ鲁马布治疗非小细胞肺癌的研究、开发及其临床活性:focus on ramucirumab in the treatment of non-small cell lung cancer: design, development, and clinical activity
Manuel Cobo,Vanesa Gutiérrez,Rosa Villatoro et al.
Manuel Cobo et al.
The vascular endothelial growth factor (VEGF) and receptor is a therapeutic target because of the importance of this pathway in carcinogenesis. This pathway regulates and promotes angiogenesis as well as increases endothelial cell prolifera...
Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives [0.03%]
非小细胞肺癌ROS1重排的检测现状及未来展望
Giulio Rossi,Genny Jocollé,Antonia Conti et al.
Giulio Rossi et al.
ROS1 rearrangement characterizes a small subset (1%-2%) of non-small cell lung cancer and is associated with slight/never smoking patients and adenocarcinoma histology. Identification of ROS1 rearrangement is mandatory to permit targeted th...
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma [0.03%]
唑来膦酸治疗恶性胸膜间皮瘤患者的初步研究
Muhammad Omer Jamil,Mary S Jerome,Deborah Miley et al.
Muhammad Omer Jamil et al.
Purpose: Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of
Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects [0.03%]
呼出气分析在肺癌早期检测中的新进展及未来前景
Inbar Nardi-Agmon,Nir Peled
Inbar Nardi-Agmon
In lung cancer, the prognosis and treatment options depend directly on tumor size and its spread at the time of diagnosis. There is therefore a constant search for methods that will allow early detection of cancerous lung nodules. With adva...
Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study [0.03%]
表皮生长因子受体阴性晚期肺腺癌化疗历程的单中心回顾性研究
Seigo Minami,Yoshitaka Ogata,Shouichi Ihara et al.
Seigo Minami et al.
Background: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has been classified by driver mutations, such as EGFR mutations. The aim of this study was to research the proporti...
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma [0.03%]
Necitumumab治疗非小细胞肺癌进展
Manish K Thakur,Antoinette J Wozniak
Manish K Thakur
The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activat...
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives [0.03%]
帕博利珠单抗在转移性非小细胞肺癌治疗中的患者选择及展望
Ashwin Somasundaram,Timothy F Burns
Ashwin Somasundaram
Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains poor. However, the approval of checkpoint blockade immunotherapy has shifted the treatment paradigm and provides hope for improved survival. ...
Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer [0.03%]
撒哈拉以南非洲非小细胞肺癌患者的驱动基因致癌基因
Barbara Legius,Sandra Van Den Broecke,Inge Muylle et al.
Barbara Legius et al.
Non-small cell lung cancer can exhibit driver oncogenes, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), that are possible targets for therapy. The prevalence of these rearranged driver oncogenes is i...
Vanessa Karen de Sá,Juliano C Coelho,Vera Luiza Capelozzi et al.
Vanessa Karen de Sá et al.
Lung cancer persists throughout the world as a major cause of death. In 2014, data from the Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer among men (second most common) and 10.930 new cases among women...
Patrick J Richard,Ramesh Rengan
Patrick J Richard
The oligometastatic disease theory was initially described in 1995 by Heilman and Weichselbaum. Since then, much work has been performed to investigate its existence in many solid tumors. This has led to subclassifications of stage IV cance...